Clinical Trials List
Protocol NumberM22-574
2024-04-01 - 2028-04-30
Phase III
Not yet recruiting2
Recruiting1
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- PO-HSIEN LI Division of Hematology & Oncology
- CHENG-HSIEN LIN Division of Hematology & Oncology
- YU-HSUAN SHIH Division of Hematology & Oncology
- PO-WEI LIAO Division of Hematology & Oncology
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- HSIN-CHEN LIN Division of Hematology & Oncology
- 鄧齡喬 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Sheng-chieh Chou Division of General Internal Medicine
- 林耘曲 Division of General Internal Medicine
- 姚 明 Division of General Internal Medicine
- 柯紀綸 Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
380 participants
